|Bid||16.00 x 1300|
|Ask||16.89 x 900|
|Day's Range||16.00 - 16.75|
|52 Week Range||2.35 - 23.34|
|Beta (3Y Monthly)||-0.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.80|
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
New clinical data gave investors pause, while management wisely took advantage of the soaring stock price to raise capital through a share offering.
NEW YORK, NY / ACCESSWIRE / December 7, 2018 / U.S. equities finished modestly lower on Thursday as trade concerns were reignited after the arrest of a Huawei senior executive. The Dow Jones Industrial ...
A “trade war truce” was expected to come from the dinner between President Trump and Chinese President Xi Jinping over the weekend and that is what exactly happened. China and the United States agreed to a ceasefire in their bitter trade war on Saturday, including no escalated tariffs in Jan. Trump will leave tariffs on $200 billion worth of Chinese imports at 10 percent at the beginning of the new year. The Nasdaq Composite Index climbed 0.79 percent to close at 7,330.54.
CV Sciences, somewhat incredibly, has risen by a factor of 21x in just the last year. CVSI stock, in fact, has risen more than 1,000% just since April. Unlike a number of OTC marijuana-related stocks, CV Sciences has a real business.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
Amarin Corporation plc (AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin. In addition, Amarin has granted the underwriters a 30-day option to purchase approximately $30.0 million of additional ADSs. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
Amarin Corporation plc (AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”). All of the shares in the proposed offering are to be sold by Amarin. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / U.S. equities lost footing on Friday amidst drop in oil prices and selloff in FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet) stocks. ...
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / U.S. equities finished mostly in the green on Friday as investors digested comments from President Donald Trump, expressing confidence in resolving the current ...
Amarin Corporation plc’s (NASDAQ:AMRN): Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s Read More...
H.C. Wainwright analysts are convinced these three biotech stocks are worth a lot more than their current market values. All have recently been given price targets that suggest they could nearly double your money, or better. Here's why these analysts are willing to stick their necks out and predict huge gains ahead for Catalyst Pharmaceuticals (CPRX), Amarin Corporation (AMRN), and Ocular Therapeutix (OCUL). As the PDUFA goal date of November 28, 2018 for Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS) is approaching, H.C. Wainwright analyst Andrew Fein expects to see a straightforward nod from the FDA.
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
In the first nine months of 2018, Amarin reported revenues of $151.3 million, which is 20.0% YoY growth. Analysts expect Amarin to report a gross margin of 75.43% in 2018, which will be a rise of 25 basis points YoY. The company is expected to witness a gross margin of 76.67% in 2019, which will be an improvement by 123 basis points YoY.